BR112012011237A2 - agente terapêutico e profilático para diabetes - Google Patents

agente terapêutico e profilático para diabetes

Info

Publication number
BR112012011237A2
BR112012011237A2 BR112012011237A BR112012011237A BR112012011237A2 BR 112012011237 A2 BR112012011237 A2 BR 112012011237A2 BR 112012011237 A BR112012011237 A BR 112012011237A BR 112012011237 A BR112012011237 A BR 112012011237A BR 112012011237 A2 BR112012011237 A2 BR 112012011237A2
Authority
BR
Brazil
Prior art keywords
therapeutic
agent
diabetes
prophylactic
sym
Prior art date
Application number
BR112012011237A
Other languages
English (en)
Inventor
Kumagai Hiroki
Kubota Naoto
Kadowaki Takashi
Takahashi Takehiro
Kubota Tetsuya
Original Assignee
Univ Tokyo
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tokyo, Toray Industries filed Critical Univ Tokyo
Publication of BR112012011237A2 publication Critical patent/BR112012011237A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

agente terapêutico e profilático para diabetes. agente terapêutico ou profiláctico para diabete compreendendo um derivado de tiazolidina como um agonista de ppar-<sym> como um componente eficaz, cujo agente mostra um efeito colateral reduzido do agonista de ppar-<sym>, é descrito. o agente terapêutico ou profiláctico para diabetes compreende um agonista de ip particular tal como beraprost sódico (bps), e um derivado de tiazolina tal como pioglitazona ou um sal farmeceuticamente aceitável do mesmo. visto que o agente terapêutico ou profiláctico da presente invenção mostra uma ação hipoglicêmica suficientemente eficaz sem ser acompanhado por efeitos colaterais característicos a agonistas de ppar-<sym>(por exemplo, ganho de peso corporal), o agente é útil como um agente terapêutico ou profiláctico altamente seguro e eficaz para diabetes.
BR112012011237A 2009-11-13 2010-11-12 agente terapêutico e profilático para diabetes BR112012011237A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009259544 2009-11-13
PCT/JP2010/070185 WO2011059053A1 (ja) 2009-11-13 2010-11-12 糖尿病の治療または予防薬

Publications (1)

Publication Number Publication Date
BR112012011237A2 true BR112012011237A2 (pt) 2019-09-24

Family

ID=43991709

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012011237A BR112012011237A2 (pt) 2009-11-13 2010-11-12 agente terapêutico e profilático para diabetes

Country Status (11)

Country Link
US (1) US9492422B2 (pt)
EP (1) EP2500020B1 (pt)
JP (1) JP5697260B2 (pt)
KR (1) KR101701943B1 (pt)
CN (1) CN102655866B (pt)
BR (1) BR112012011237A2 (pt)
CA (1) CA2780683A1 (pt)
ES (1) ES2525748T3 (pt)
MX (1) MX2012005500A (pt)
TW (1) TWI513462B (pt)
WO (1) WO2011059053A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034393B1 (ru) 2012-11-13 2020-02-03 Адосиа Состав инсулина быстрого действия, содержащий замещенное анионное соединение
JO3624B1 (ar) 2014-05-08 2020-08-27 Lilly Co Eli تركيبات إنسولين سريعة المفعول
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
CN110934866B (zh) * 2018-09-25 2023-12-01 深圳微芯生物科技股份有限公司 西格列羧及其相关化合物的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5229318B2 (pt) 1972-03-30 1977-08-01
AR205004A1 (es) 1973-10-30 1976-03-31 Ishikawa M Procedimiento para preparar derivados de 6,8-dialquil-7-alcoxi-carbonil-4-hidroximetil-1-ftalazona y la 7,8-lactona
JPS5724786B2 (pt) 1973-10-31 1982-05-26
GB1583961A (en) 1976-05-11 1981-02-04 Wellcome Found Prostacyclin and derivatives thereof
JPS5495552A (en) 1978-01-06 1979-07-28 Sankyo Co Ltd Prostacyline derivative and its preparation
JPS54130543A (en) 1978-03-31 1979-10-09 Ono Pharmaceut Co Ltd Prostagladin i2 analog, and its preparation
JPS55313A (en) 1978-06-13 1980-01-05 Kissei Pharmaceut Co Ltd Imidazole derivative
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
DE2845770A1 (de) 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
JPS58219162A (ja) 1982-06-14 1983-12-20 Takeda Chem Ind Ltd 置換ビニルカルボン酸誘導体およびその製造法
JPS59137445A (ja) 1983-01-27 1984-08-07 Teijin Ltd プロスタサイクリン類及びその製法
JPS59141536A (ja) 1983-02-01 1984-08-14 Sumitomo Chem Co Ltd 新規ビシクロオクタン誘導体
DE3306123A1 (de) 1983-02-18 1984-09-06 Schering AG, 1000 Berlin und 4709 Bergkamen Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPS6130519A (ja) 1984-07-23 1986-02-12 Dainippon Pharmaceut Co Ltd 脳神経細胞の酸素欠乏性疾患治療剤
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
DE3504677A1 (de) 1985-02-12 1986-08-14 A. Nattermann & Cie GmbH, 5000 Köln Neue imidazol-2-yloxyalkansaeuren und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
JPH072640B2 (ja) 1986-06-05 1995-01-18 科研製薬株式会社 抗高脂血症剤
JPS6453672A (en) 1987-08-24 1989-03-01 Nec Corp Audio response type b board of exchange
EP0330025B1 (en) 1988-02-23 1994-10-12 Teijin Limited Antidiabetic composition comprising isocarbacyclin derivative
DE3932403A1 (de) 1989-05-12 1991-04-11 Thomae Gmbh Dr K Neue arylsulfonamide, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JP3062230B2 (ja) 1989-12-05 2000-07-10 財団法人相模中央化学研究所 シス―ビシクロ〔４．３．０〕ノナ―２―エン誘導体
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
JPH10251146A (ja) 1997-03-11 1998-09-22 Toray Ind Inc 糖尿病性神経障害の治療方法
JP4314742B2 (ja) 1997-09-16 2009-08-19 東レ株式会社 Ｃ−ｃケモカイン産生抑制剤
EP1028113A4 (en) 1998-08-04 2004-10-13 Toray Industries HETEROCYCLIC DERIVATIVES OF BENZENE IN FUSION AND THEIR USE
TWI316055B (pt) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
HUP0300990A2 (hu) 2003-04-15 2005-05-30 SynoSens Kutató és Fejlesztő Kft. Szinergista gyógyszer-kombináció a diabetesz megelőzésére vagy kezelésére
KR101187693B1 (ko) * 2003-05-09 2012-10-05 도레이 카부시키가이샤 신장질환의 치료 또는 예방제
CA2565154A1 (en) * 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
WO2006034510A2 (en) * 2004-09-22 2006-03-30 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
JP2006199694A (ja) * 2004-12-24 2006-08-03 Ono Pharmaceut Co Ltd Ｇｌｐ−１産生増強剤
GT200600046A (es) * 2005-02-09 2006-09-25 Terapia de combinacion
PT1894567E (pt) * 2005-06-03 2012-11-21 Mitsubishi Tanabe Pharma Corp Agentes farmacêuticos concomitantes e sua utilização

Also Published As

Publication number Publication date
EP2500020A1 (en) 2012-09-19
WO2011059053A1 (ja) 2011-05-19
CN102655866B (zh) 2013-11-13
TWI513462B (zh) 2015-12-21
JPWO2011059053A1 (ja) 2013-04-04
CA2780683A1 (en) 2011-05-19
ES2525748T3 (es) 2014-12-29
KR101701943B1 (ko) 2017-02-02
US20120258988A1 (en) 2012-10-11
TW201127387A (en) 2011-08-16
EP2500020A4 (en) 2013-02-06
MX2012005500A (es) 2012-08-03
EP2500020B1 (en) 2014-09-10
JP5697260B2 (ja) 2015-04-08
CN102655866A (zh) 2012-09-05
US9492422B2 (en) 2016-11-15
KR20120087987A (ko) 2012-08-07

Similar Documents

Publication Publication Date Title
DOP2017000156A (es) Derivados de glucagón con estabilidad mejorada
BR112015010977A2 (pt) derivado de piridina, sal farmaceuticamente aceitável do mesmo ou solvato do mesmo, pró-droga, composição farmacêutica, inibidor do urat1, agente para o tratamento ou prevenção de uma ou mais doenças, e, composto
BR112018001217A2 (pt) dispositivo de controle de dose para dispositivos de entrega de fármaco injetável
CL2019001842A1 (es) Nuevos derivados de fenilo.
ECSP099618A (es) Compuestos anulares fusionados como agonistas parciales de ppar-gamma
GT201500293A (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso
CR20120345A (es) Derivados de 3-hidroxi-5-arilisotiazol novedosos
BR112015032623A2 (pt) composto, composição farmacêutica, métodos para tratar doenças e condições, e para degradar o receptor de estrogênio, usos de um composto e de uma combinação, e, combinação
CL2007002197A1 (es) Compuestos derivados de indol; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes mellitus, retinopatia diabetica, hiperglucemia, hiperl
GT200700064A (es) Agonistas de ep2
BRPI0815057B8 (pt) composto, composição farmacêutica, e, uso de um composto
BR112012011237A2 (pt) agente terapêutico e profilático para diabetes
BR112017014740A2 (pt) composto espiro tricíclico
BR112012004851B8 (pt) uso de um derivado de tiazol
BR112012013252A2 (pt) composição farmacêutica tópica, preservativo, composto, e, uso do mesmo
BR112013017302A2 (pt) formulações de imunossupressor
BR112012015084A2 (pt) composição farmacêutica de liberação lenta de iloperidone
AR062401A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis
BR112018075221A2 (pt) micropartículas compreendendo um composto contendo enxofre
BR112015026259A2 (pt) combinações de ligantes de adrenoceptor alfa-2 e receptor sigma
PH12016502405A1 (en) 2-acylaminothiazole derivative or salt thereof
CO2021011023A2 (es) Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos
BR112016029888A2 (pt) composições parasiticidas compreendendo derivados de indol, métodos e usos dos mesmos
EP4234021A3 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy
BR112012018154A2 (pt) agonista alfa-2 adrenérgico tendo longa duração do efeito de redução da pressão intraocular

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.